MGMT and glioblastoma: This is supported in literature by Skardley et al.24 who reported an overall decrease in survival time by 0.88 with each 10cm3 residual tumor volume after surgical resection in glioblastoma, yet the variability in grading of extent of resection is still a cause of controversy yielding variable cutoff values for EOR with different survival outcomes.25,26 Both IDH mutation and MGMT promoter methylation are also reported to affect overall survival in patients with glioblastoma, yet the local literature is from private institutions where patient affordability is not an issue.27-30